Score Your Stock

US stock · figures in US dollars · scored on full-year results

Moderna Moderna, Inc.

MRNA · Healthcare · Biotechnology
Bottom 1% of scored stocks
WeakBottom 1% of scored stocks
Weak SpotRecent Loss

Moderna scores 21/100 on fundamentals: in the bottom 1% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (67/100); its weakest is Business Strength (0/100). It carries 2 warning flags: Weak Spot, Recent Loss.

Best
Financial 67
Weakest
Business 0
Price 0
  • Carries a Weak Spot flag
  • Carries a Recent Loss flag

An expensively priced stock with shrinking sales, but business strength needs attention.

What looks good
What to watch
Mkt capUS$ 88.5b#146 of 503 in the S&P 500EPSUS$ -7.98P/En/m (loss-making)P/B13.1×✗ vs sector median 3.7×Div yieldNo dividends paidBottom 7% in the S&P 50052w range · 86% of range22.28254.48
as of 31 Oct 2026

Nearby peers

Ranks #60 of 60 in Healthcare by score

#1Universal Health Services79#56Henry Schein35#57Becton Dickinson31#58Gilead Sciences31#59Charles River Laboratories24
#60Moderna21

One-Minute Summary

Why Moderna scores 21

An expensively priced stock with shrinking sales, but business strength needs attention.

What looks good
What to watch

Business Strength

0
Why 0?
Pillar score: (0 + 0 + 0 + 0 + 0) = 0 of 10 points → 0
Return on Equity (ROE)-47%Weak4-Year Revenue Growth-31%/yrWeak4-Year Profit Growthn/m (loss-making)WeakNet Profit Marginn/m (loss-making)WeakQuarterly Momentumn/m (loss-making)Weak
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↑ +33.2%Equity ↓ -51.2%ROE % -46.6%
Net ProfitEquityROE %
-4.7b-3.6b-2.8b-3.2b13.9b10.9b8.7b6.8b202320242025TTM-34%-32.7%-32.6%-46.6%

Revenue & Net Profit, with Net Margin

Revenue ↓ -67.3%Net Profit ↑ +33.2%Net Margin % -142.6%
RevenueNet ProfitNet Margin %
6.8b3.2b1.9b2.2b-4.7b-3.6b-2.8b-3.2b202320242025TTM-69.8%-111.3%-146.8%-142.6%

Sales shrank about 67.3% over 4 years: the business is getting smaller, which needs a good explanation.

The company lost money in recent years: the bars below zero are losses, not profits.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↓ -92.3%Net Profit ↓ -6,115.4%Net Margin % -546.9%
RevenueNet ProfitNet Margin %
1.9b966m108m137m1.0b676m389m143m13m-1.1b-971m-825m-200m-826m-1.3b-782mQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'260.7%-115.9%-899.1%-602.2%-20%-122.2%-345.2%-546.9%
▲▼▼▼▼▼▼▼

Sales fell about 92.3% over the last 8 quarters: worth watching why.

The company made a loss in at least one of the last 8 quarters: the bars below zero are losses, not profits.

Why 67?
Pillar score: (2 + 2 + 0) = 4 of 6 points → 67
Debt-to-Equity0.2×StrongCurrent Ratio2.3×StrongInterest Coverage-72.5×Weak
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt ↑ +3.5%Equity ↓ -51.2%D/E 0.2×
Total DebtEquityD/E
1.2b747m1.3b1.3b13.9b10.9b8.7b6.8b202320242025TTM0.1×0.1×0.2×0.2×

Borrowings have stayed roughly level: manageable, as long as profits stay healthy.

Short-term assets vs bills, with Current Ratio

Current Assets ↓ -43.7%Current Liabilities ↓ -16%Current Ratio 2.3×
Current AssetsCurrent LiabilitiesCurrent Ratio
10.3b8.1b6.5b5.8b3.0b2.2b2.0b2.5b202320242025TTM3.4×3.7×3.3×2.3×
Why 13?
Pillar score: (0 + 0 + 0 + 1) = 1 of 8 points → 13
Dividend QualityNo dividends paidWeak
Payout ratio: -0%
Operating Cash FlowNegative recentlyWeakFree Cash FlowNegative recentlyWeakCash & Cash EquivalentsPartly healthyOkay
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↑ +65.6%Free CF ↑ +67.5%
Operating CFFree CF
-3.1b-3.0b-1.9b-1.1b-3.8b-4.1b-2.1b-1.2b202320242025TTM

Cash flow has been weak or negative recently: the business is burning cash, not building it.

Cash vs Total Debt

Cash ↓ -40.7%Short-Term Debt ↑ +108%Total Debt ↑ +3.5%
CashShort-Term DebtTotal Debt
2.9b1.9b2.6b1.7b25m37m42m52m1.2b747m1.3b1.3b202320242025TTM

Dividends per Share, with Yield

DPS (cents) → +0%Yield % 0%
DPS (cents)Yield %
000020222023202420250%0%0%0%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 0?
Pillar score: (0 + 0 + 0) = 0 of 6 points → 0
P/E Ration/m (loss-making)WeakP/B Ratio13.1×WeakPEG Ration/m (growth not measurable)Weak
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 225.00US$ 124.36US$ 23.72Oct '25Feb '26Jun '26Oct '26

The share price is up about 716.3% over the past year.

Why 25?
Pillar score: (0 + 1 + 2 + 0 + 0 + 0) = 3 of 12 points → 25
Earnings ConsistencyVery bumpyWeakDebt Trend (4yr)StableOkayShare Count Trend (4yr)+1%/yrStrongInventory vs Sales (4yr)+42.6 pp/yr vs salesWeakAsset Turnover Trend (4yr)-45%WeakQuarterly ConsistencyLoss in 7 of 8 quartersWeak
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↓ -67.3%Inventory ↑ +38.6%Inv. % of Rev. 12.7%
RevenueInventoryInv. % of Rev.
6.8b3.2b1.9b2.2b202m117m153m280m202320242025TTM3%3.7%8%12.7%
Ranks #60 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#56Henry Schein35#57Becton Dickinson31#58Gilead Sciences31#59Charles River Laboratories24
#60Moderna (you)21

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDiv yieldP/E RatioP/B Ratio
2026US$ 2.2bUS$ -3.2bUS$ -1.1bUS$ -1.2bUS$ -171.0mUS$ 1.7bUS$ 1.3bUS$ 52.0mUS$ 6.8bUS$ 5.8bUS$ 2.5bUS$ 11.0bUS$ 4.2bUS$ 280.0m--47%-143%0.2×2.3×-72.5×---
2025US$ 1.9bUS$ -2.8bUS$ -1.9bUS$ -2.1bUS$ -202.0mUS$ 2.6bUS$ 1.3bUS$ 42.0mUS$ 8.7bUS$ 6.5bUS$ 2.0bUS$ 12.3bUS$ 3.7bUS$ 153.0mUS$ 0.0m-33%-147%0.2×3.3×-275.8×0%-4.3×1.4×
2024US$ 3.2bUS$ -3.6bUS$ -3.0bUS$ -4.1bUS$ -1.1bUS$ 1.9bUS$ 747.0mUS$ 37.0mUS$ 10.9bUS$ 8.1bUS$ 2.2bUS$ 14.1bUS$ 3.2bUS$ 117.0mUS$ 0.0m-33%-111%0.1×3.7×-149.3×0%-4.6×1.5×
2023US$ 6.8bUS$ -4.7bUS$ -3.1bUS$ -3.8bUS$ -707.0mUS$ 2.9bUS$ 1.2bUS$ 25.0mUS$ 13.9bUS$ 10.3bUS$ 3.0bUS$ 18.4bUS$ 4.6bUS$ 202.0mUS$ 0.0m-34%-70%0.1×3.4×-111.5×0%-8.1×2.7×